Prazosin for PTSD Nightmares: What the Veteran Trial Found

The treatment target matters: nightmares, sleep quality and overall PTSD symptoms need separate assessment.

What PACT measured

PACT randomized 304 veterans with chronic post-traumatic stress disorder (PTSD); only seven were women. Prazosin or placebo was gradually increased, with divided daytime/bedtime doses capped at 20 mg daily for men and 12 mg for women.¹

At 10 weeks, nightmares, sleep quality and global improvement showed no significant advantage over placebo. The nightmare-score difference was 0.2 points (95% CI −0.3 to 0.8). Missing outcomes were excluded from primary analyses. VA funded the trial without industry involvement.¹

Psychosocial instability was excluded. The selected, predominantly male population limits conclusions for women and civilians.¹

Why guidance remains specific

The 2023 VA/DoD guideline gives a weak recommendation for prazosin for PTSD-associated nightmares, with low confidence in the evidence. Its review includes studies beyond PACT. It separately weakly recommends against prazosin as monotherapy for overall PTSD symptoms and prioritizes specific trauma-focused psychotherapies for PTSD.²

A weak recommendation supports an individualized discussion, with expected benefits, unwanted effects and preferences considered. It does not promise that the medicine will help a particular person.²

Ask the clinician to identify the symptom being targeted. For a nightmare-focused plan, agree how you will track nightmare nights, distress on waking and difficulty returning to sleep, and when you will review the pattern. Keep that review alongside the broader PTSD care plan.

Did I Do That in My Sleep? includes “Nightmares and Night Terrors,” with suggestions for a brief symptom record and seeking care that respects a trauma history.

Blood pressure needs a plan

At 10 weeks, supine systolic blood pressure fell 6.7 mm Hg more than with placebo.¹

Prazosin’s US labeled indication is hypertension; PTSD-nightmare treatment is off-label. The label warns about fainting, usually within 30–90 minutes of the first dose, and sometimes after rapid dose increases or adding another blood-pressure medicine. Other antihypertensives and PDE-5 inhibitors can add to blood-pressure lowering.³

Tell the prescriber about fainting, dizziness on standing, other medicines and planned cataract surgery. Ask for written starting instructions, how changes will be supervised, and who to contact if dizziness or fainting occurs. The trial’s maximum doses are not starting instructions.

The label advises avoiding driving or hazardous tasks for the first 24 hours after starting and after dose increases. Getting up slowly may help with positional dizziness.³